Errata (DOI:10.1016/j.transproceed.2006.12.029);Report of the Experience With Enteric-Coated Sodium Mycophenolate in a De Novo Population of Kidney Transplant Recipients at High Risk for Delayed Graft Function

Transplantation Proceedings

Volumn 39, Issue 3, 2007, Pages 600-601

  Novoa, P ^a   Rodriguez L ^a   Gutierrez L ^a  

^a HOSPITAL PRIVADO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID; RAPAMYCIN; STEROID;

ADULT; ARTICLE; BANFF GRADE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERIC COATED TABLET; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL INFECTION; GRAFT FAILURE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG INFECTION; MALE; MICROEMULSION; NEPHROTOXICITY; PRIORITY JOURNAL; RATING SCALE; SEPSIS; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION;

EID: 34147117589     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.004     Document Type: Erratum

References (11)

1. Sollinger H.W., and U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60 (1995) 225
2. Meier Kriesche H.U., Steffen B., Hochberg A.M., et al. Long term use of mycophenolate mofetil is associated with a reduction in incidence and risk of late rejection. Am J Transplant 3 (2003) 68
3. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: etiology, incidence and management. Drug Saf 24 (2001) 645
4. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
5. Knoll G.A., MacDonald I., Khan A., et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
6. Hardinger K.L., Brenan D.C., Lowell J., et al. Long term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17 (2004) 609
7. Massari P., Duro Garcia V., Giron F., et al., PROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 37 (2005) 916
8. Ojo A.O., Wolfe R.A., Held P.J., et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 63 (1997) 968
9. Shaw L.M., Holt D.W., Oellerich M., et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a round table discussion. Ther Drug Monit 23 (2001) 305
10. Gonzalez-Roncero F.M., Gentil M.A., Brunet M., et al. Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. Transplant Proc 37 (2005) 3749
11. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver renal transplantation. Transplantation 61 (1996) 1029